MARKET

AXDX

AXDX

Accelerate
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.60
-0.22
-2.24%
Opening 10:22 03/03 EST
OPEN
9.87
PREV CLOSE
9.82
HIGH
9.88
LOW
9.51
VOLUME
27.47K
TURNOVER
--
52 WEEK HIGH
19.11
52 WEEK LOW
4.530
MARKET CAP
553.04M
P/E (TTM)
-6.8684
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Renaissance Of The Moonshot Era
Investing in Potentially World-Altering Innovation
Benzinga · 1d ago
10-K: ACCELERATE DIAGNOSTICS, INC
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations The following Management's...
Edgar Online - (EDG = 10Q, 10K) · 1d ago
Analysts Have Just Cut Their Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Revenue Estimates By 27%
Market forces rained on the parade of Accelerate Diagnostics, Inc. ( NASDAQ:AXDX ) shareholders today, when the...
Simply Wall St. · 3d ago
Covid-19 Diagnostic Market 2021 Sales, Size, Share, Growth and Trend Forecast to 2026
Feb 24, 2021 (Heraldkeepers) -- Covid-19 Diagnostic Industry Description The report provides a holistic summary of basic, secondary and advanced information...
Heraldkeepers · 6d ago
Global Covid-19 Test Market | Industry Size, Trends, Share, Analysis, Forecast To 2027
Japan, Japan, Tue, 23 Feb 2021 23:21:02 / Comserve Inc. / -- Competitive Analysis: Abbott Diagnostics, Accelerate Diagnostics, Expedeon Ltd., Ador...
Comserve · 02/24 04:21
DJ Accelerate Diagnostics, Inc. CEO Jack Phillips on Q4 2020 Results -- Earnings Call Transcript >AXDX
Dow Jones · 02/24 02:11
Accelerate Diagnostics Q4 EPS $(0.33) Misses $(0.32) Estimate, Sales $3.10M Miss $4.12M Estimate
Accelerate Diagnostics (NASDAQ:AXDX) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.32) by 3.13 percent. The company reported quarterly sales of $3.10 million which
Benzinga · 02/23 21:36
Accelerate Diagnostics 4Q Sales $3.1M >AXDX
Accelerate Diagnostics 4Q Sales $3.1M >AXDX
Dow Jones · 02/23 21:33
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AXDX. Analyze the recent business situations of Accelerate through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AXDX stock price target is 12.33 with a high estimate of 17.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 180
Institutional Holdings: 31.55M
% Owned: 54.77%
Shares Outstanding: 57.61M
TypeInstitutionsShares
Increased
41
993.27K
New
29
-785.95K
Decreased
24
1.53M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-2.28%
Healthcare Equipment & Supplies
-2.13%
Key Executives
Chairman/Independent Director
John Patience
Chief Executive Officer/Chief Operating Officer/Director
John Phillips
Chief Financial Officer
Steve Reichling
Senior Vice President
Ron Price
Other
Nedal Safwat
Independent Director
Thomas Brown
Independent Director
Tom Brown
Independent Director
Roland Diggelmann
Independent Director
Louise Francesconi
Independent Director
Mark Miller
Independent Director
Jack Schuler
Independent Director
Matthew Strobeck
Independent Director
Frank ten Brink
Independent Director
Charles Watts
  • Dividends
  • Splits
  • Insider Activity
No Data
About AXDX
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

Webull offers kinds of Accelerate Diagnostics Inc stock information, including NASDAQ:AXDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXDX stock methods without spending real money on the virtual paper trading platform.